// App-Quantinova.ai

890 : RPPA-Based Protein Profiling Reveals Enhanced PI3K/AKT/mTOR Signaling in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Patients with Low CD200 Expression

Researchers

Presenter

  • Valentina Serafin

Principal Investigators

  • Pieter Rondou

  • Tim Lammens

  • Frank Speleman

  • Benedetta Accordi

  • Barbara De Moerloose

  • Pieter Van Vlierberghe

Medical Centers

  • Department of Womens and Childrens Health, Laboratory of Oncohematology, University of Padua, Padua, Italy

  • Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

  • Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium

  • Cancer Research Institute Ghent (CRIG), Ghent, Belgium

Locations

  • Belgium

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • 26S protease regulatory subunit S10B

  • Mitogen-activated protein kinase

  • Nucleoside diphosphate kinase A

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Integrin alpha-4

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved